Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark
European Heart Journal - Cardiovascular Pharmacotherapy · 2024
DOI: 10.1093/ehjcvp/pvae043 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Anton Pottegård und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense 5230, Denmark. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, Registries, Primary Prevention. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Examine whether the low-density lipoprotein cholesterol (LDL -C) determination method influences the rate of statin initiation for primary prevention of cardiovascular disease. Methods and results We conducted a register-based retrospective study in the Region of Southern Denmark. Two hospital-based laboratories in the region directly measure LDL -C whereas four laboratories calculate LDL -C using Friedewald's formula. Physicians do not choose which method is used. We included all statin-naïve patients ≥40 years with no history of cardiovascular disease, diabetes, or chronic kidney disease, who had their LDL -C determined during 2018–2019. There were 202 807 people who had LDL -C determined during the study period (median age 59 years, 44% women) of which 37% had a direct LDL -C measurement. The median reported LDL -C was 3.40 mmol/L [interquartile range (IQR) 2.90–4.00] for those with a direct measurement vs. 3.00 mmol/L (IQR 2.40–3.50) for those with calculated LDL -C. For those with direct measurement, re-calculated LDL -C (using Friedewald's formula) was 0.35 mmol/L lower than the reported direct LDL -C measurement. Among those with directly measured LDL -C, 3.6% initiated statins compared with 2.7% of those with a calculated LDL -C. Direct LDL -C measurement led to higher odds of having a statin initiated compared with calculated LDL -C (adjusted odds ratio 1.23, 95% CI 1.17–1.30); for those with triglycerides >1.7 mmol/L the adjusted odds ratio was 1.41 (95% CI 1.30–1.52).
Conclusion
Differences in the reporting of LDL -C from laboratories using different methods have a substantial influence on physician's decisions to prescribe statins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, University of Southern Denmark, Odense 5230, Denmark.
- Independent Scholar.
- Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark 6000, Denmark.
- Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver V6T 1Z3, Canada.
- Research Unit of General Practice, University of Southern Denmark, Odense 5230, Denmark.
ORCID-Profile: Anton Pottegård
Zitieren
APA
Pottegård, A., Gerdes, L. U., Wetche, J. L., & Thompson, W. (2024). Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae043
Vancouver
Pottegård A, Gerdes LU, Wetche JL, Thompson W. Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae043
BibTeX
@article{Pottegrd2024,
author = {Pottegård, Anton and Gerdes, Lars Ulrik and Wetche, Jakob Langballe and Thompson, Wade},
title = {Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2024},
doi = {10.1093/ehjcvp/pvae043}
}
EUVIMED